PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.13 EPS

PepGen (NASDAQ:PEPG) issued its quarterly earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13, Zacks reports.

PepGen Trading Down 4.9 %

Shares of PEPG opened at $1.37 on Monday. The business’s 50 day moving average is $2.56 and its 200 day moving average is $5.87. The company has a market capitalization of $44.66 million, a PE ratio of -0.46 and a beta of 1.53. PepGen has a 12-month low of $1.16 and a 12-month high of $19.30.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PEPG. HC Wainwright decreased their price objective on shares of PepGen from $26.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Wedbush dropped their price target on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Bank of America downgraded PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Monday, December 16th.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.